--- schema_version: "secwatch.filing_event.v1" accession: "0001104659-23-084851" form_type: "8-K" ticker: "AEON" cik: "0001837607" company_name: "AEON Biopharma, Inc." filed_at: "2023-07-27T23:59:59+00:00" generated_at: "2026-06-13T00:54:23.804878+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.65 calibrated_materiality_score: 0.65 confidence: "high" source: SEC EDGAR --- # AEON Biopharma (f/k/a Priveterra) closes business combination; ~37.2M shares outstanding ## Summary - 1,445,112 shares redeemed at ~$10.63/share ($21.29M); remaining $5.92M trust used to fund deal. - Old AEON shareholders received ~2.328 AEON shares per Old AEON share; Sponsor 6.9M shares (3.45M unvested). - $40M interim notes converted into 5,797,611 shares; $7M PIPE for 1M shares at $7.00 per share. - Forward purchase agreements with ACM ARRT J and Polar for up to 7.5M shares; FPA funding PIPE of 6.275M shares. - Common stock and warrants began trading on NYSE American on July 24, 2023 under AEON and AEON WS. ## SEC filing metadata - accession: 0001104659-23-084851 - form_type: 8-K - ticker: AEON - cik: 0001837607 - company_name: AEON Biopharma, Inc. - filed_at: 2023-07-27T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.65 - calibrated_materiality_score: 0.65 - confidence: high - sec_items: 1.01, 2.01, 5.06, 3.02, 3.03, 5.03, 4.01, 5.01, 5.02, 5.05, 7.01, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/0001104659-23-084851-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/tm2314948d1_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001104659-23-084851 - JSON: https://secwatch.observer/filing/0001104659-23-084851.json - Plain text: https://secwatch.observer/filing/0001104659-23-084851.txt ## Key facts - Auditor Changes AEON Biopharma, Inc. dismissed WithumSmith + Brown LLP as its auditor. - Action: dismissal - Auditor: WithumSmith + Brown LLP source text: On July 21, 2023, the Audit Committee of the Board dismissed WithumSmith + Brown LLP (“Withum”), Priveterra’s independent registered public accounting firm prior to the Business Combination, as the Company’s independent registered public accounting firm effective upon consummation of the Closing. evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/0001104659-23-084851-index.htm - Governance Changes AEON Biopharma, Inc.: Amended and Restated Bylaws approved and adopted on July 21, 2023, effective immediately prior to the Business Combination (effective 2023-07-21). - Change: bylaw amendment - Effective: 2023-07-21 source text: On July 21, 2023, the Board approved and adopted the Amended and Restated Bylaws of AEON (the “Bylaws”), which became effective immediately prior to the completion of the Business Combination. evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/0001104659-23-084851-index.htm - Governance Changes AEON Biopharma, Inc.: Company ceased being a shell company as a result of the Business Combination. - Change: shell status source text: As a result of the Business Combination, the Company ceased being a shell company. evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/0001104659-23-084851-index.htm - Governance Changes AEON Biopharma, Inc.: Amended and Restated Certificate of Incorporation effective July 21, 2023 (effective 2023-07-21). - Change: charter amendment - Effective: 2023-07-21 source text: The Amended and Restated Certificate of Incorporation of AEON (the “Certificate of Incorporation”), which became effective upon filing with the Secretary of State of the State of Delaware on July 21, 2023 includes the amendments proposed by the Charter Proposals. evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/0001104659-23-084851-index.htm - Governance Changes AEON Biopharma, Inc.: New Code of Business Conduct and Ethics adopted on July 21, 2023 (effective 2023-07-21). - Change: code of ethics - Effective: 2023-07-21 source text: on July 21, 2023, AEON’s board of directors approved and adopted a new Code of Business Conduct and Ethics applicable to all employees, officers and directors of AEON. evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/0001104659-23-084851-index.htm - M&A Transactions AEON Biopharma, Inc. underwent a change of control involving Old AEON Biopharma, Inc. (closed 2023-07-21). - Action: change of control - Counterparty: Old AEON Biopharma, Inc. - Closing: 2023-07-21 source text: Pursuant to the terms and subject to the conditions set forth in the Business Combination Agreement, following the Special Meeting, on July 21, 2023 (the “Closing Date”), the Transactions were consummated (the “Closing”). evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/0001104659-23-084851-index.htm - Material Agreements AEON Biopharma, Inc. entered into Business Combination Agreement with Priveterra, Priveterra Merger Sub, Inc. and AEON Biopharma, Inc. (effective 2022-12-12). - Action: entry - Agreement: merger - Counterparty: Priveterra, Priveterra Merger Sub, Inc. and AEON Biopharma, Inc. - Effective: 2022-12-12 source text: on December 12, 2022, Priveterra entered into a business combination agreement (the “Business Combination Agreement”) with Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra (“Merger Sub”) and AEON Biopharma, Inc., a Delaware corporation (“Old AEON”). evidence_url: https://www.sec.gov/Archives/edgar/data/1837607/000110465923084851/0001104659-23-084851-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.